CXCL10 overexpression
|
GBM
|
CXCL10 overexpression
|
GBM
|
aflibercept intravitreal Sensitive: C3 – Early Trials
|
aflibercept intravitreal Sensitive: C3 – Early Trials
|
CXCL10 overexpression
|
RCC
|
CXCL10 overexpression
|
RCC
|
pembrolizumab + axitinib Sensitive: C3 – Early Trials
|
pembrolizumab + axitinib Sensitive: C3 – Early Trials
|